Digital Health Reimbursement in Europe: Lessons from the German DiGA Model

Reimbursing software is not the same as reimbursing a medicine or a device. Germany’s DiGA pathway remains the clearest European example of a dedicated route, and it shows what payers expect from digital health evidence.

The German model in outline

The Digital Healthcare Act of 2019 created a fast-track route for digital health applications (DiGA). Once a product is entered in the national directory, it becomes eligible for prescription and reimbursement within statutory health insurance. The directory began in September 2020. A provisional listing is possible on the basis of preliminary evidence and can last for up to 12 months; if adequate evidence is not provided in that time, the product is removed from the list.

What the model demands

Even with a fast-track label, the pathway sets requirements.

  • A product that qualifies as a medical device of lower risk class and meets the relevant device regulation.
  • Evidence that the application delivers a benefit to patients, to be built up during the provisional period if necessary.
  • Compliance with data protection and security expectations, which are central for software handling health data.
  • A clear intended use and a prescribing pathway that clinicians can follow.

Details of the criteria are set by the competent German authority and should be checked against current guidance before planning.

Implications beyond Germany

Other countries have introduced or are developing their own approaches, and these differ in scope and maturity. Companies should not assume that a German listing transfers elsewhere. Each system defines evidence, prescribing and payment differently, and in many Member States there is no dedicated pathway, so products may fall under general device or service reimbursement arrangements. In Greece, medical devices sit outside the formal medicines HTA process, which is a separate consideration to plan for.

Building the evidence early

The common lesson is that evidence generation should start at product design. A study that measures a patient-relevant outcome, a clear comparator such as usual care, and a plan for real-world data after launch will support almost any reimbursement route that follows.

Regulatory foundations come first

Reimbursement discussions start from a regulatory position. Software with a medical purpose is regulated under the EU medical device framework, and its classification, clinical evaluation and post-market obligations determine what can be claimed. Payers will not engage seriously with a product whose intended purpose or conformity assessment is unclear.

It is therefore sensible to settle classification, intended use and clinical evaluation before building the reimbursement case, and to keep technical documentation consistent with the claims made to payers. Where a product uses artificial intelligence or processes sensitive personal data, further requirements may apply, and these should be checked as part of the planning rather than discovered at the point of listing.

How PQRA helps

PQRA can help map the regulatory classification of a digital product under the EU medical device framework, identify the reimbursement routes available in each target market, and plan the evidence needed.

To discuss reimbursement options for a digital health product, Contact PQRA.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *